An Executed Plan to Combat COVID-19 in the United States

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019. To date, this coronavirus is responsible for greater than 90 million cases in the United States and more than 1 million confirmed deaths. When this virus came to the United States, testing was unorganized, no effectiv...

Full description

Saved in:
Bibliographic Details
Published in:Advances in anesthesia 2022-12, Vol.40 (1), p.45-62
Main Author: Hartman, William R.
Format: Article
Language:English
Subjects:
Antivirals
Convalescent plasma
COVID screening
COVID-19
COVID-19 Vaccines - therapeutic use
Humans
Monoclonal antibodies
Pandemic
SARS-CoV-2
United States - epidemiology
Vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019. To date, this coronavirus is responsible for greater than 90 million cases in the United States and more than 1 million confirmed deaths. When this virus came to the United States, testing was unorganized, no effective treatments were known, and no vaccines had been discovered. A plan to correct these deficiencies through cooperative science and efficient clinical trials was implemented to combat this novel virus. This plan developed efficient and inexpensive tests, highly effective medicines to treat and prevent disease progression, and vaccines to immunize the population.
ISSN:0737-6146
1878-0415
DOI:10.1016/j.aan.2022.07.002